SCHEMBL6793054

SCHEMBL6793054

Cc1c(OS(=O)(=O)O)ccc2c1cc(C(=O)NC(=N)N)n2C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.33
KDM4E B2RXH2 4/20 0.33
LMNA P02545 3/20 0.33
GALR3 O60755 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SLC9A1 P19634 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
POLB P06746 1/20 0.33
PHGDH O43175 4/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
THRB P10828 1/20 0.32
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793058 0.89 MAPT (0.34) MAPTKDM4ELMNAGALR3GAA
SCHEMBL6796151 0.85 SLC9A1 (0.39) MAPTKDM4ELMNAGALR3GAA
SCHEMBL6795754 0.83 KMT2A (0.34) MAPTKDM4ELMNAMAPK1HSD17B10
SCHEMBL6793076 0.81 GAA (0.33) MAPTKDM4ELMNAGALR3GAA
SCHEMBL6799899 0.79 KDM4E (0.35) MAPTKDM4ELMNAMAPK1HSD17B10
SCHEMBL6794680 0.79 PHGDH (0.34) GALR3GAASLC9A1PHGDH
SCHEMBL6796789 0.78 KMT2A (0.32) MAPTKDM4ELMNAMAPK1HSD17B10
SCHEMBL6798954 0.77 GALR3 (0.49) MAPTKDM4ELMNAGALR3GAA
SCHEMBL7246268 0.77 ALDH1A1 (0.41) MAPTKDM4ELMNAGAAHSD17B10
Water SCHEMBL6797065 0.77 KMT2A (0.32) MAPTKDM4ELMNAMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 MAPT 4395/4885KDM4E 1068/4885LMNA 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.